Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 24752340)

1.

Active surveillance for metastatic or recurrent renal cell carcinoma.

Park I, Lee JL, Ahn JH, Lee DH, Lee KH, Jeong IG, Song C, Hong B, Hong JH, Ahn H.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1421-8. doi: 10.1007/s00432-014-1680-9. Epub 2014 Apr 22.

PMID:
24752340
2.

First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.

Matsubara N, Mukai H, Naito Y, Itoh K, Komai Y, Sakai Y.

Urology. 2013 Jul;82(1):118-23. doi: 10.1016/j.urology.2013.03.035.

PMID:
23806397
3.

Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.

Rautiola J, Utriainen T, Peltola K, Joensuu H, Bono P.

Acta Oncol. 2014 Jan;53(1):113-8. doi: 10.3109/0284186X.2013.794957. Epub 2013 May 30.

PMID:
23721300
4.

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.

Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.

J Urol. 2001 Jul;166(1):68-72.

PMID:
11435825
5.

Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.

Pal SK, Nelson RA, Vogelzang N.

PLoS One. 2013 May 3;8(5):e63341. doi: 10.1371/journal.pone.0063341. Print 2013.

6.

Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.

Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, Kihara K.

Eur Urol. 2009 May;55(5):1145-53. doi: 10.1016/j.eururo.2008.10.012. Epub 2008 Oct 14.

PMID:
18930583
7.

A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.

Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ.

Invest New Drugs. 2013 Aug;31(4):1008-15. doi: 10.1007/s10637-013-9931-1. Epub 2013 Jan 26.

PMID:
23354849
8.

The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.

Dirican A, Kucukzeybek Y, Somali I, Erten C, Demir L, Can A, Bahriye Payzin K, Vedat Bayoglu I, Akyol M, Koseoglu M, Alacacioglu A, Oktay Tarhan M.

J BUON. 2013 Apr-Jun;18(2):413-9.

PMID:
23818354
9.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ.

J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.

10.

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, Rini BI, Choueiri TK.

Cancer. 2011 Jun 15;117(12):2637-42. doi: 10.1002/cncr.25750. Epub 2010 Nov 18.

11.

Predictive factors for late recurrence in patients with stage T1 clear cell renal cell carcinoma: a multiinstitutional study.

Ha YS, Park YH, Kang SH, Hong SH, Hwang TK, Byun SS, Kim YJ.

Clin Genitourin Cancer. 2013 Mar;11(1):51-5. doi: 10.1016/j.clgc.2012.08.008. Epub 2012 Sep 25.

PMID:
23017336
12.

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.

Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK.

Ann Oncol. 2012 Jun;23(6):1549-55. doi: 10.1093/annonc/mdr533. Epub 2011 Nov 5.

13.

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

D' Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.

Curr Cancer Drug Targets. 2012 Jul;12(6):693-702.

PMID:
22463589
14.

Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Pal SK, Jones JO, Carmichael C, Saikia J, Hsu J, Liu X, Figlin RA, Twardowski P, Lau C.

Urol Oncol. 2013 Nov;31(8):1826-31. doi: 10.1016/j.urolonc.2012.04.007. Epub 2012 May 17.

15.

Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.

Levy A, Menard J, Albiges L, Loriot Y, Di Palma M, Fizazi K, Escudier B.

Eur J Cancer. 2013 May;49(8):1898-904. doi: 10.1016/j.ejca.2013.02.003. Epub 2013 Mar 13.

PMID:
23490648
16.

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.

Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM.

Ann Oncol. 2011 May;22(5):1048-53. doi: 10.1093/annonc/mdq563. Epub 2010 Nov 29.

17.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.

J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.

18.

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ.

J Natl Cancer Inst. 2011 May 4;103(9):763-73. doi: 10.1093/jnci/djr128. Epub 2011 Apr 28.

19.

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.

Iacovelli R, Lanoy E, Albiges L, Escudier B.

BJU Int. 2012 Dec;110(11):1747-53. doi: 10.1111/j.1464-410X.2012.11518.x. Epub 2012 Oct 26.

PMID:
23106948
20.

Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.

Kontovinis L, Laschos K, Karadimou A, Andreadis C, Bamias A, Paraskevopoulos P, Dimopoulos M, Papazisis K.

Med Oncol. 2012 Jun;29(2):750-4. doi: 10.1007/s12032-010-9815-6. Epub 2011 Jan 30.

PMID:
21279702
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk